Dual-acting angiotensin receptor-neprilysin inhibition

Current Hypertension Reports

Volumn 13, Issue 1, 2011, Pages 74-78

  Segura, Julian ^a   Ruilope, Luis M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Angiotensin receptor blocker; Antihypertensive therapy; Blood pressure control; Comparative study; Dose response relationship; NEP; Neprilysin inhibition; Neutral endopeptidase; Valsartan

Indexed keywords

AHU 377; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENKEPHALINASE INHIBITOR; FOSINOPRIL; LCZ 696; MEMBRANE METALLOENDOPEPTIDASE; NATRIURETIC FACTOR; OMAPATRILAT; PLACEBO; UNCLASSIFIED DRUG; VALSARTAN; VASOPEPTIDASE INHIBITOR;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG POTENTIATION; ENZYME INHIBITION; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; NONHUMAN; PROTEIN TARGETING; SINGLE DRUG DOSE; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD VOLUME; ENDOPEPTIDASES; HEART FAILURE; HUMANS; HYPERTENSION; NEPRILYSIN; RECEPTOR, ANGIOTENSIN, TYPE 1; TETRAZOLES; VALINE; VASOCONSTRICTION;

EID: 79551565930     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0166-7     Document Type: Article

References (29)

1. JD Neaton D Wentworth 1992 Serum cholesterol blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316, 099 white men. Multiple Risk Factor Intervention Trial Research Group Arch Intern Med 152 56 64 1:STN:280:DyaK387gt1ejsw%3D%3D 10.1001/archinte.152.1.56 1728930
2. S Lewington R Clarke N Qizilbash, et al. 2002 Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903 1913 10.1016/S0140-6736(02)11911-8 12493255 (Pubitemid 35472129)
3. DE Weiner H Tighiouart MG Amin, et al. 2004 Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies J Am Soc Nephrol 15 1307 1315 10.1097/01.ASN.0000123691.46138.E2 15100371 (Pubitemid 38526012)
4. PM Kearney M Whelton K Reynolds, et al. 2005 Global burden of hypertension: analysis of worldwide data Lancet 365 217 223 15652604
5. G Mancia G De Backer A Dominiczak, et al. 2007 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 1105 1187 1:CAS:528:DC%2BD2sXmtlWnsr0%3D 10.1097/HJH.0b013e3281fc975a 17563527 (Pubitemid 46924065)
6. AV Chobanian GL Bakris HR Black, et al. 2003 National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2560 2572 1:CAS:528:DC%2BD3sXjvFCqtrk%3D 10.1001/jama.289.19.2560 12748199 (Pubitemid 37430158)
7. F Turnbull 2003 Blood Pressure Lowering Treatment Trialists Collaboration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials Lancet 362 1527 1535 1:CAS:528:DC%2BD3sXovVWlsro%3D 10.1016/S0140- 6736(03)14739-3 14615107 (Pubitemid 37410190)
8. MR Law JK Morris NJ Wald 2009 Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies BMJ 338 b1665 1:STN:280:DC%2BD1Mzls1KrsQ%3D%3D 10.1136/bmj.b1665 19454737
9. K Wolf-Maier RS Cooper H Kramer, et al. 2004 Hypertension treatment and control in five European countries, Canada, and the United States Hypertension 43 10 17 1:CAS:528:DC%2BD3sXpvVeqtr8%3D 10.1161/01.HYP.0000103630.72812.10 14638619 (Pubitemid 38031904)
10. ER Levin DG Gardner WK Samson 1998 Natriuretic peptides N Engl J Med 339 321 328 1:CAS:528:DyaK1cXlsVOit7Y%3D 10.1056/NEJM199807303390507 9682046 (Pubitemid 28366422)
11. KN Pandey 2005 Biology of natriuretic peptides and their receptors Peptides 26 901 932 1:CAS:528:DC%2BD2MXks1CnsL0%3D 10.1016/j.peptides.2004.09. 024 15911062 (Pubitemid 40725366)
12. DG Gardner S Chen DJ Glenn CL Grigsby 2007 Molecular biology of the natriuretic peptide system: implications for physiology and hypertension Hypertension 49 419 426 1:CAS:528:DC%2BD2sXhsVShsr8%3D 10.1161/01.HYP. 0000258532.07418.fa 17283251
13. EG Bevan JM Connell J Doyle, et al. 1992 Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension J Hypertens 10 607 613 1:STN:280:DyaK38zjtlSrsg%3D%3D 10.1097/00004872-199207000- 00002 1321186
14. AM Richards GA Wittert IG Crozier, et al. 1993 Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II J Hypertens 11 407 416 1:CAS:528:DyaK3sXkvVGltL4%3D 10.1097/00004872-199304000-00011 8390508
15. S Ando MA Rahman GC Butler, et al. 1995 Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin Hypertension 26 1160 1166 1:CAS:528:DyaK28XmslOgug%3D%3D 7498988
16. CJ Ferro JC Spratt 1998 Haynes et al.: Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo Circulation 97 2323 2330 1:CAS:528:DyaK1cXkt1OjtLs%3D 9639376
17. DJ Campbell 2003 Vasopeptidase inhibition: a double-edged sword? Hypertension 41 383 389 1:CAS:528:DC%2BD3sXhsV2lurY%3D 10.1161/01.HYP. 0000054215.71691.16 12623931 (Pubitemid 36314604)
18. JC Burnett Jr 1999 Vasopeptidase inhibition: a new concept in blood pressure management J Hypertens 17 Suppl 1 S37 S43 1:CAS:528:DyaK1MXktlegsrk%3D
19. JA Robl CQ Sun J Stevenson, et al. 1997 Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase J Med Chem 40 1570 1577 1:CAS:528:DyaK2sXjtFSjtbY%3D 10.1021/jm970041e 9171867 (Pubitemid 27231460)
20. NC Trippodo JA Robl MM Asaad, et al. 1998 Effects of omapatrilat in low, normal, and high renin experimental hypertension Am J Hypertens 11 3 Pt 1 363 372 1:CAS:528:DyaK1cXisFyrtbc%3D 10.1016/S0895-7061(97)00404-4 9544878 (Pubitemid 28186749)
21. WC Liao O Vesterqvist C Delaney, et al. 2003 Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects Br J Clin Pharmacol 56 395 406 1:CAS:528:DC%2BD3sXosFCls7k%3D 10.1046/j.1365-2125.2003.01888.x 12968984 (Pubitemid 37188134)
22. JJ Nawarskas JR Anderson 2000 Omapatrilat: a unique new agent for the treatment of cardiovascular disease Heart Dis 2 266 274 1:CAS:528: DC%2BD3cXks1Wjtr0%3D 11728268
23. GF Mitchell JL Izzo Jr Y Lacourcière, et al. 2002 Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the Conduit Hemodynamics of Omapatrilat International Research Study Circulation 105 2955 2961 1:CAS:528:DC%2BD38XlslSjsbk%3D 10.1161/01.CIR.0000020500.77568.3C 12081987 (Pubitemid 34693826)
24. JB Kostis M Packer HR Black, et al. 2004 Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial Am J Hypertens 17 103 111 1:CAS:528: DC%2BD2cXmvF2gtw%3D%3D 10.1016/j.amjhyper.2003.09.014 14751650 (Pubitemid 38125125)
25. RM Fryer J Segreti PN Banfor, et al. 2008 Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema Br J Pharmacol 153 947 955 1:CAS:528:DC%2BD1cXislWis7Y%3D 10.1038/sj.bjp.0707641 18084312 (Pubitemid 351328937)
26. M Cicardi LC Zingale L Bergamaschini A Agostoni 2004 Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment Arch Intern Med 164 910 913 10.1001/archinte.164.8.910 15111379 (Pubitemid 38520634)
27. J Gu A Noe P Chandra, et al. 2010 Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) J Clin Pharmacol 50 401 414 1:CAS:528:DC%2BC3cXks1Clt7o%3D 10.1177/ 0091270009343932 19934029
28. LM Ruilope A Dukat M Böhm, et al. 2010 Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study Lancet 375 1255 1266 1:CAS:528:DC%2BC3cXksFClsbw%3D 10.1016/S0140-6736(09) 61966-8 20236700
29. S Julius SE Kjeldsen M Weber, et al. 2004 Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2022 2031 1:CAS:528:DC%2BD2cXltVCitro%3D 10.1016/S0140-6736(04)16451-9 15207952 (Pubitemid 38781102)